•
Sep 30, 2024
Rigel Q3 2024 Earnings Report
Rigel reported positive third-quarter and year-to-date net income, driven by strong revenue growth across its commercial portfolio and the acquisition of GAVRETO.
Key Takeaways
Rigel Pharmaceuticals reported a net income of $12.4 million for the third quarter of 2024, with total revenues of $55.3 million. The company's growth was driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO, as well as contract revenue from collaborations.
Total revenues for Q3 2024 were $55.3 million, including $26.3 million from TAVALISSE, $5.5 million from REZLIDHIA, and $7.1 million from GAVRETO.
Net income for Q3 2024 was $12.4 million, or $0.71 per share basic and $0.70 per share diluted.
TAVALISSE sales increased by 8% compared to the same period in 2023.
REZLIDHIA sales increased by 107% compared to the same period in 2023.
Rigel
Rigel
Forward Guidance
No specific forward guidance was provided in the press release.